Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine
暂无分享,去创建一个
[1] D. Kiesewetter,et al. Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model , 2012, The Journal of Nuclear Medicine.
[2] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[3] S. Lyons,et al. Imaging Mouse Models of Cancer. , 2015, Cancer journal.
[4] S. Orsulic,et al. Mouse models of cancer. , 2011, Annual review of pathology.
[5] R. Weissleder,et al. Imaging in the era of molecular oncology , 2008, Nature.
[6] Giovanni Parmigiani,et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.
[7] S. Modi,et al. HER2 breast cancer therapies: a review , 2009, Biologics : targets & therapy.
[8] Robert A. Weinberg,et al. Comparative Biology of Mouse versus Human Cells: Modelling Human Cancer in Mice O P I N I O N , 2022 .
[9] Todd E Peterson,et al. Molecular Imaging: 18F-FDG PET and a Whole Lot More* , 2009, Journal of Nuclear Medicine Technology.
[10] Andrew L. Kung,et al. Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.
[11] M. Rossing,et al. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.
[12] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[13] G. Hospers,et al. PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma , 2012, The Journal of Nuclear Medicine.
[14] Aik Choon Tan,et al. Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.
[15] Christof Fellmann,et al. Stable RNA interference rules for silencing , 2013, Nature Cell Biology.
[16] M. Washington,et al. A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells , 2014, Clinical Cancer Research.
[17] Eliot T. McKinley,et al. [18F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study , 2015, Annals of Nuclear Medicine.
[18] Karlyne M. Reilly,et al. Genetically engineered mouse models in cancer research. , 2010, Advances in cancer research.
[19] David A. Tuveson,et al. Maximizing mouse cancer models , 2007, Nature Reviews Cancer.
[20] P. Pandolfi,et al. A co-clinical platform to accelerate cancer treatment optimization. , 2015, Trends in molecular medicine.
[21] V. Cryns,et al. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.
[22] M. Junttila,et al. Translational value of mouse models in oncology drug development , 2015, Nature Medicine.
[23] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[24] C. Dence,et al. Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer , 2012, The Journal of Nuclear Medicine.
[25] Jason I. Herschkowitz,et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.
[26] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[27] Ping Zhao,et al. Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer , 2009, Clinical Cancer Research.
[28] Hakmook Kang,et al. Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts , 2015, Molecular Imaging and Biology.
[29] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.
[30] Lewis C Cantley,et al. The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.
[31] Yasuyoshi Watanabe,et al. 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients , 2015, EJNMMI Research.
[32] Andrew L. Kung,et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.
[33] P. Pandolfi,et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.
[34] Samir J. Courdy,et al. Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine , 2013, Current protocols in pharmacology.
[35] Peter J Houghton,et al. Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.
[36] Gerhard Christofori,et al. Mouse models of breast cancer metastasis , 2006, Breast Cancer Research.
[37] Eliot T. McKinley,et al. 3′-Deoxy-3′-[18F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer , 2014, PloS one.
[38] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[39] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[40] A. Nunn,et al. (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. , 2015, Nuclear medicine and biology.
[41] J. P. Kennedy,et al. Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells , 2009, Clinical Cancer Research.
[42] John N. Hutchinson,et al. Transgenic mouse models of human breast cancer , 2000, Oncogene.
[43] S. Schnitt,et al. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.